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BACKGROUND: Adjuvant! Online is an internet-based computer programme providing 10-year prognosis predictions for early breast
cancer patients. It was developed in the United States, has been successfully validated in Canada, and is used in the United Kingdom
and elsewhere. This study investigates the performance of Adjuvant! in a cohort of patients from the United Kingdom.
METHODS: Data on the prognostic factors and management of 1065 women with early breast cancer diagnosed consecutively at the
Churchill Hospital in Oxford between 1986 and 1996 were entered into Adjuvant! to generate predictions of overall survival (OS),
breast cancer-specific survival (BCSS), and event-free survival (EFS) at 10 years. Such predictions were compared with the observed
10-year outcomes of these patients.
RESULTS: For the whole cohort, Adjuvant! significantly overestimated OS (by 5.54%, Po0.001), BCSS (by 4.53%, Po0.001), and EFS
(by 3.51%, P¼0.001). For OS and BCSS, overestimation persisted across most demographic, pathologic, and treatment subgroups
investigated. Differences between Adjuvant! predicted and observed EFS appeared smaller, and were significant for far fewer
subgroups, only 5 out of the 28. The likely explanation for such discordance is that US breast cancer mortality rates (upon which
Adjuvant! is based) appear to be systematically lower than breast cancer mortality rates in the United Kingdom. Differences in survival
after recurrence would seem to be one contributory factor, with data suggesting that prognosis after relapse appears poorer in the
United Kingdom. This may reflect the fact that new and more effective cancer drugs are often only approved for use in the United
Kingdom many years after their adoption in the United States.
CONCLUSION: The use of Adjuvant! by clinicians within the UK National Health Service is increasing, under the assumption that the
programme is transferrable to the United Kingdom. At least for women treated for breast cancer at the Churchill Hospital in Oxford,
however, Adjuvant!’s predictions were on the whole overoptimistic. If the findings reported here could be shown to be generalisable
to other areas of the United Kingdom, then thought should perhaps be given to the development of a UK-specific version of the
programme.
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The decision about whether to administer adjuvant systemic therapy
to women diagnosed with early invasive breast cancer is complex
and requires the synthesis of information on likely prognosis,
treatment effectiveness, and patient preferences. Statistical models or
programmes that use established prognostic markers to predict
outcomes for early breast cancer patients to aid this decision-making
process have greatly increased in recent years.
In the United Kingdom, the Nottingham Prognostic Index (NPI)
is one of the few prognostic models that have been widely used by
clinicians to help inform the selection of women with early breast
cancer for adjuvant systemic therapy (Blamey et al, 1979; Haybittle
et al, 1982; Todd et al, 1987). On the basis of a simple Cox
proportional hazards model and using routinely collected data on
tumour stage, size, and grade, the NPI is simple to compute, its
predictions demonstrate good discriminative ability, and it has
been successfully validated (Todd et al, 1987; Galea et al, 1992;
Sundquist et al, 1999). Use of the NPI, however, is somewhat
limited with clinicians able only to calculate a patient’s index score
and then to reference the relevant life table survival curve from a
series of prognostic groups constructed by the authors. With the
hazard function from the model not ever having been reported, it
is not possible to use the NPI in conjunction with estimates of
treatment efficacy to generate prognoses for individual patients
both before and after any proposed therapy.
Adjuvant! Online (http://www.adjuvantonline.com) is a web-
based programme, which is increasingly being used by oncologists
in the United Kingdom and which can generate such patient level
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sprognosis predictions (Ravdin et al, 2001; Siminoff et al, 2006).
Developed in the United States and published in 2001,
users can input information on a patient’s age, oestrogen receptor
(ER) status, tumour grade, tumour size, and number of positive
nodes, and obtain predictions of 10-year overall survival (OS)
(the likelihood of being alive 10 years after the diagnosis of
breast cancer was first carried out), breast cancer-specific
survival (BCSS) (the likelihood of not dying of breast cancer
within 10 years of diagnosis), and event-free survival (EFS)
(the likelihood of surviving 10 years without recurrence (local,
regional or distant), a second primary breast cancer, or death from
breast cancer), both with and without any proposed adjuvant
therapy. The performance of Adjuvant! has been evaluated in
small cohorts of patients in Germany, and the programme was
successfully validated in a large population of Canadian women
with early breast cancer in 2005 (Olivotto et al, 2005; Euler et al,
2006; Schmidt et al, 2009). To date, Adjuvant! has not been
subjected to a similar validation exercise in the United Kingdom.
Given the increasingly widespread use of the programme by
clinicians working in the National Health Service (NHS), it is
important to assess the performance of the Adjuvant! Online
programme by comparing its 10-year predictions with observed
outcomes for early breast cancer patients in the United Kingdom.
This paper reports the findings from such a study.
Adjuvant!
For the purpose of this analysis, it is helpful first to understand
how the predictions made by Adjuvant! are generated. The
programme is based upon data collected from women aged 20–79
years who underwent primary surgery for invasive breast cancer
between 1988 and 1992 and who were entered into the US
Surveillance, Epidemiology, and End-Results (SEER) tumour registry
database (Adjuvant! Online, 2005a). The SEER tumour registry
follows approximately 10% of all breast cancer cases in the United
States and records data on patient demographics, tumour character-
istics, and survival. Since its initial development, Adjuvant! has been
updated a number of times so as to incorporate longer term patient
follow-up data, more reliable information on cause of death, and the
most recent evidence on treatment efficacy. The current version
(Version 8) is based upon the observed 10-year survival experiences
of women in the tumour registry and robust estimates of treatment
effect taken predominantly from the 2005 Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) overviews (Early Breast
Cancer Trialists’ Collaborative Group, 2005).
Users of Adjuvant! can enter information on the following
prognostic factors: ER status (positive, negative, undefined),
tumour grade (1, 2, 3, undefined), tumour size (0.1–1cm, 1.
1–2cm, 2.1–3cm, 3.1–5cm, 45cm), and the number of positive
nodes (0, 1–3, 4–9, 49). The programme then ‘looks up’ the
annual breast cancer mortality rates, which correspond to the
combination of prognostic factors entered. The rates returned are
those derived from women in the SEER tumour registry with the
same combination of specified prognostic factors, and are then
subsequently used within an actuarial survival analysis to facilitate
patient-level prognosis prediction as follows: a 100% survival
probability at time zero (diagnosis) in the model is re-calculated
after 1 year as 100% minus the patient’s age-adjusted probability of
dying from causes other than breast cancer during that year (taken
from US life table data), and also minus the patient’s expected
probability of dying from breast cancer during that year
(calculated as described above). From the resulting survival
probability at year 1, this process is then repeated again, and
annually thereafter, out to 10 years to give an estimate of OS.
Breast cancer-specific survival is given by 100% minus the 10-year
cumulative probability of dying from breast cancer.
Using this actuarial approach, the principal aim of Adjuvant! is
to generate estimates of 10-year outcomes both with and without
adjuvant systemic therapy. Estimation of the latter requires that
the annual breast cancer mortality rates used reflect the level of
risk in the absence of treatment. Some women in the SEER registry
would have received adjuvant therapy; however, treatment data
were not recorded. It was necessary therefore for analysts
developing Adjuvant! to adjust for the expected frequency and
benefit of this adjuvant therapy to be able to generate predictions
of breast cancer mortality (and ultimately OS and BCSS) ‘without
treatment’. The programme was then designed to model the likely
effects of any planned adjuvant therapy (hormone therapy,
chemotherapy, or both, as specified by the user). As detailed
above, the estimates of treatment effect used by Adjuvant! are
taken from the published literature. Such relative risks are applied
to the programme’s ‘without treatment’ breast cancer mortality
rates and through the actuarial approach described above,
Adjuvant! then provides a prediction of the likely improvement
in prognosis (OS and BCSS) offered by adjuvant therapy.
In addition to OS and BCSS, Adjuvant! also provides predictions
of EFS. The SEER registry however collects no information on
cancer recurrence, and so Adjuvant!’s ‘without treatment’ recur-
rence probabilities are determined indirectly from its ‘without
treatment’ breast cancer mortality predictions (further informa-
tion is provided in the Discussion section).
MATERIALS AND METHODS
The study cohort comprised all breast cancer patients diagnosed
consecutively between 1986 and 1996 at the Churchill Hospital in
Oxford - this hospital operates a regional referral service, receiving
patients from across the county of Oxfordshire (total population
approximately 635500) and the surrounding areas (Oxfordshire
County Council, 2008). For each woman in the cohort, histo-
pathology reports and treatment record sheets provided informa-
tion on tumour characteristics and treatments administered.
Patients were followed up on an annual basis through the Cancer
Intelligence Network and General Practitioners, who returned
information on recurrence and survival status.
As Adjuvant! was developed for ‘adjuvant’ decision-making in
those where benefit is less certain, from this cohort we excluded
women with locally advanced disease (those with T3 (45cm
tumour) and T4 (tumour of any size growing into the skin or chest
wall) tumours, and those with N2 (4–9 nodes involved) and N3 (10
or more lymph nodes involved) tumours), and women with
metastatic disease (M1). By excluding such patients, our approach
is consistent with that of the Canadian validation study; however,
we do acknowledge that these women would still have been
considered for and probably would have received systemic
hormonal therapy or chemotherapy or both.
To the remaining women in the study cohort, we applied the
following eligibility criteria: patients must be aged 85 years or less,
have complete data on nodal status, tumour size, and adjuvant
systemic therapy, have undergone complete local therapy (that is,
radiotherapy given if breast conserving surgery was conducted),
and have complete 10-year follow-up.
Treatment protocol
During 1986 to 1996, the surgical treatment protocol at the
Churchill Hospital was for breast conservation followed by
radiotherapy, with mastectomy reserved for larger and more
central tumours. The sampling of at least four nodes was
recommended (median¼6, range 1–26) and in the first instance,
women found to be node positive and under the age of 60 years
were administered adjuvant intravenous CMF chemotherapy. Over
time however, as evidence emerged on the effects of adjuvant
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schemotherapy in broader groups of patients, therapy was extended
to more women (e.g., ER-negative older women). Five years of
tamoxifen was prescribed for all patients known to have ER-
positive tumours. No other factors in addition to the five featured
in the Adjuvant! programme were routinely used to select women
for adjuvant therapy.
Data analysis
For each eligible woman, Adjuvant! standard version 8 was used
to generate 10-year predictions of OS, BCSS, and EFS. Such
predictions were obtained by entering into the programme
information on each patient’s age, tumour size, number of positive
nodes, grade, ER status, and adjuvant systemic therapies received
(types of hormone and chemotherapies). In line with the Canadian
validation study, all predictions were made with Adjuvant!’s
comorbidity assumption set at the default of ‘minor problems’.
Observed 10-year outcomes for each woman were available from
the Churchill Hospital data set. Comparisons between predicted
and observed outcomes (OS, BCSS, and EFS) were conducted for
the whole cohort, and for clinically important subgroups. For each
of these separate analyses, Kaplan–Meier survival analysis
provided observed 10-year percentages. Predicted 10-year percen-
tages were given by averaging over the relevant Adjuvant!
predictions. In line with the Canadian validation study, we
considered Adjuvant! reliable enough for clinical use if predicted
and observed outcomes were within 2% of one another (Olivotto
et al, 2005). Statistical uncertainty around these differences was
assessed by way of a t-test, the statistic for which was calculated by
dividing the difference between predicted and observed percen-
tages by s.e. for the observed percentages. A P-value of less than
0.05 was used to indicate statistical significance in the first
instance. Given the need to perform multiple testing, however, we
also later consider a more stringent definition of significance of
Po0.01.
RESULTS
Between 1986 and 1996, 1696 women with invasive breast cancer
were treated consecutively at the Churchill Hospital in Oxford.
From this cohort we excluded 315 (18.6%) women with locally
advanced or metastatic disease. Of the remaining 1381 women, 316
(22.9%) were considered ineligible and were excluded from this
study for the following reasons: age greater than 85 (n¼1),
unknown tumour size or nodal status (n¼158), unknown
adjuvant systemic therapy (n¼5), incomplete local therapy
(breast conserving surgery without radiotherapy) (n¼78), and
follow-up less than 10 years (n¼74). This left 1065 women with
T1-2, N0, M0 tumours. All 1065 of these patients were available for
the analysis of OS, but BCSS and EFS could be estimated for only
1058 patients as a consequence of missing data on relapse status
and cause of death. Tables 1–3 present patient demographic,
pathologic and treatment characteristics, and comparisons be-
tween Adjuvant! predicted and observed 10-year OS, BCSS and
EFS, respectively.
Considering OS first, Table 1 shows that for nearly all analyses
performed, the trends in both predicted and observed OS across
different subgroups largely conformed with prior expectation. For
example, predicted and observed OS in patients without nodal
involvement (80.69 and 75.99%, respectively) were greater than
predicted and observed OS in patients with nodal involvement
(70.03 and 62.65%, respectively). Similar intuitive trends were
observed for tumour grade and tumour size.
Comparing Adjuvant! predicted and observed 10-year OS data
shows that Adjuvant! almost continuously overestimated this
outcome, and in several cases significantly so. Predicted and
observed OS were within 2% of each other only for women with an
unknown tumour grade (77.20 vs 77.46%, difference¼ 0.26%)
and an ER negative status (71.66 vs 69.73, difference¼1.93%).
From Table 2, which shows BCSS, it can be seen that both
predicted and observed outcomes generally increase with age.
Competing risk explains this phenomenon, with older patients
much more likely to die from other causes than from breast cancer.
Comparing Adjuvant! predicted and observed 10-year BCSS data
showed that, as for OS, predictions made by the online programme
are almost all higher than observed patient outcomes. A
comparison of the data contained within Tables 1 and 2 reveals
that predicted and observed OS and BCSS were significantly
different for many of the same subgroups.
Event-free survival is shown in Table 3. As for OS and BCSS,
trends in predicted and observed EFS across different clinical
subgroups are intuitive. In contrast to OS and BCSS, however,
differences between Adjuvant! predicted and observed outcomes
appear smaller, and are significant for far fewer subgroups, only 5
out of 28 (excluding 16 patients over age of 76 years). Furthermore,
observed outcomes are within 2% of predicted outcomes for six of
the subgroup analyses performed.
For the cohort as a whole, Adjuvant!’s predictions for all three
outcomes were significantly greater than the observed outcomes.
For OS, the difference between predicted and observed was 5.54%
(Po0.001), for BCSS, 4.53% (Po0.001), and for EFS, 3.51%
(P¼0.001). For each outcome we also rank ordered patients on the
basis of their Adjuvant! predictions, categorised the cohort into 5%
prognosis intervals, and estimated the mean predicted outcome for
each group. These mean predictions were then plotted against the
observed outcomes for each group as shown in Figure 1.
Figure 1A shows the relationship between predicted and
observed OS, and shows that with the exception of three of the
groups (where patient numbers were smallest) all points plotted
were below the 45 degree line illustrative of perfect agreement
between predicted and observed outcomes. Figure 1B, showing
BCSS, can be interpreted similarly, however here the magnitude of
discrepancy between predicted and observed outcomes was far less
consistent across the range of prognoses. Event-free survival is
shown in Figure 1C, which illustrates that for five of the groups
constructed, Adjuvant!’s predictions were close to observed
outcomes.
DISCUSSION
Adjuvant! Online is a web-based tool from which one can obtain
individualised prognosis predictions both with and without
adjuvant therapy for women with early breast cancer. Initially
developed using data from the SEER registry in the United States,
the tool is now used by oncologists to aid clinical decision-making
in a number of different countries including Canada, Australia,
and the United Kingdom. In 2005, Adjuvant! (version 5.0) was
successfully validated in Canada by comparing its 10-year
predictions with the actual outcomes of women diagnosed with
early breast cancer in British Colombia (Olivotto et al, 2005). In
that study, which included 4083 patients and informed the format
of the analyses presented here, overall predicted and observed
10-year outcomes were within 1% for OS, BCSS, and EFS. For the
same demographic, pathologic, and treatment subgroups shown in
Tables 1–3 of this paper, predicted and observed outcomes were
almost all within 2%. The authors concluded that Adjuvant!
performed reliably in that population. Until now no similar study
has examined the performance of Adjuvant! in the United
Kingdom.
The data presented in Tables 1–3 of this paper showed that
although both Adjuvant! predictions and observed outcomes
generally displayed the expected trends across demographic,
pathologic, and treatment subgroups, Adjuvant!’s estimates of
outcome were almost consistently (and in some cases significantly)
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sgreater than the observed outcomes of the women in the Churchill
Hospital data set. In seeking possible explanations for these
findings, we focussed first upon our patient cohort, working to
establish that they were indeed a representative sample of the
wider population of breast cancer patients in the United Kingdom.
If patients from Oxfordshire and its surrounding areas were
atypical, more specifically if they had higher rates of breast cancer
mortality and all-cause mortality than the UK population norm,
then this would provide a possible explanation for the findings
reported here and at the same time would preclude any general-
isation of the results to the rest of the United Kingdom, where
Adjuvant! might in fact perform better.
In terms of breast cancer mortality, data from the UK’s Office
for National Statistics were available to show that the prognosis of
breast cancer patients in the Thames Valley Region (which
encompasses Oxfordshire and its surrounding counties) is no
worse than that of breast cancer patients in England as a whole
(Office for National Statistics, 2004a, 2005, 2006a, 2006b). No
significant differences existed between country and regional level
5-year age-standardised survival rates for women diagnosed with
the disease in 1995–97, 1996–98, and 1997–99. Indeed for patients
diagnosed between 1994 and 1996 (the earliest years with data
available), 5-year survival in the Thames Valley region was actually
better than for England as a whole (77%, 95% CI: 76–79% vs
74.9%, 95% CI: 74.5–75.3%) (Office for National Statistics, 2004a).
Similarly, data were available to show that all-cause mortality in
Oxfordshire is lower than the UK population norm (Office for
National Statistics, 2004b). The Standardised Mortality Ratio
Table 1 Comparison of Adjuvant! 10-year overall survival predictions with observed 10-year outcomes for 1065 women presenting at the Churchill
Hospital in Oxford between 1986 and 1996
Patients % Overall survival
Demographic, pathologic,
and treatment characteristics No. %
Adjuvant!
prediction Observed s.e. Difference
All patients 1065 100 77.37 71.83 1.38 5.54
w
Age, years
20–35 34 3.19 78.74 76.47 7.27 2.27
36–50 363 34.08 82.29 77.96 2.18 4.33*
51–65 458 43.00 78.47 74.45 2.04 4.02*
66–75 194 18.22 67.32 55.15 3.57 12.17
w
X76 16 1.50 53.11 50.00 12.50 3.11
Menopausal status
Pre 397 37.28 81.98 77.83 2.08 4.15*
Post 668 62.72 74.62 68.26 1.80 6.36
w
Histology
Ductal 799 75.02 76.99 70.71 1.61 6.28
w
Lobular 116 10.89 78.25 74.14 4.07 4.11
Other 150 14.08 78.69 76.00 3.49 2.69
Grade
1 152 14.27 87.20 83.55 3.01 3.65
2 421 39.53 78.55 71.50 2.20 7.05
w
3 248 23.29 69.50 59.68 3.11 9.82
w
Unknown 244 22.91 77.20 77.46 2.68  0.26
Nodal involvement
Negative 733 68.83 80.69 75.99 1.58 4.70
w
Positive 332 31.17 70.03 62.65 2.65 7.38
w
Tumour size
0.1–1cm 150 14.08 88.77 82.67 3.09 6.10
1.1–2cm 471 44.23 82.15 75.58 1.98 6.57
w
2.1–5cm 444 41.69 68.45 64.19 2.28 4.26
ER status
Negative 261 24.51 71.66 69.73 2.84 1.93
Positive 495 46.48 79.91 70.91 2.04 9.00
w
Unknown 309 29.01 78.12 75.08 2.46 3.04
Local therapy
BCS+RT 822 77.18 78.98 74.94 1.51 4.04
w
Mast+RT 119 11.17 69.51 58.82 4.51 10.69*
Mast, no RT 124 11.64 74.22 63.71 4.32 10.51*
Systemic therapy
None 252 23.66 77.98 71.83 2.83 6.15*
Hormones only 585 54.93 77.30 72.82 1.84 4.48*
Chemotherapy only 83 7.79 74.97 66.27 5.19 8.70
Hormones+chemotherapy 145 13.62 77.95 71.03 3.77 6.92
Abbreviations: BCS¼breast conserving surgery; ER¼oestrogen receptor; Mast¼mastectomy; RT¼radiotherapy. *Po0.05,
wPo0.01.
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s(SMR) for the area (a measure comparing actual deaths against
expected deaths based upon the mortality rates of the UK
population) is 90, thus indicating that local mortality rates are
low compared with the national average (an SMR of 100 would
have indicated mortality rates equivalent to the UK population
norm).
On the basis of these data, one can postulate that the prognoses
of the women in our study are likely to be similar, if not slightly
better, than those of breast cancer patients in the United Kingdom
as a whole. These observations imply that the findings reported
here are likely to be representative for the rest of the United
Kingdom and so raise the question as to whether there are
systematic differences between breast cancer patients in the United
States and the United Kingdom, which might explain the optimism
of Adjuvant!’s predictions.
In the remainder of the discussion, we attempt to answer this
question. Figure 2 (developed by the authors based upon
Adjuvant!’s documentation) serves to remind the reader about
how Adjuvant! was developed. The first bar in Figure 2 shows the
10-year outcome data available from the SEER registry (survival,
and breast cancer and other cause mortality). The second bar
depicts how upward adjustments were made to breast cancer
mortality probabilities to account for the effects of the adjuvant
therapy that women in the SEER registry would likely have
received (recall this information was not available). The final bar
illustrates how, in the absence of data on recurrence, the
Table 2 Comparison of Adjuvant! 10-year breast cancer specific survival predictions with observed 10-year outcomes for 1058 women presenting at the
Churchill Hospital in Oxford between 1986 and 1996
Patients % Breast Cancer-specific survival
Demographic, pathologic,
and treatment characteristics No. %
Adjuvant!
prediction Observed s.e. Difference
All patients 1058 100 84.76 80.23 1.25 4.53
w
Age, years
20–35 34 3.21 79.61 78.94 7.08 0.67
36–50 361 34.12 84.69 80.07 2.12 4.62*
51–65 454 42.91 85.36 81.85 1.84 3.51
66–75 193 18.24 84.41 75.13 3.81 9.28*
X76 16 1.51 84.63 91.67 7.98  7.04
Menopausal status
Pre 395 37.33 84.25 79.98 2.03 4.27*
Post 663 62.67 85.07 80.31 1.60 4.76
w
Histology
Ductal 793 74.95 84.49 80.43 1.45 4.06
w
Lobular 115 10.87 85.10 77.25 3.92 7.85*
Other 150 14.18 85.97 81.80 3.23 4.17
Grade
1 152 14.37 95.00 93.71 2.03 1.29
2 420 39.70 86.18 80.29 1.99 5.89
w
3 243 22.97 76.01 69.91 3.04 6.10*
Unknown 243 22.97 84.66 81.88 2.50 2.78
Nodal involvement
Negative 729 68.90 88.43 84.90 1.36 3.53
w
Positive 329 31.10 76.64 69.91 2.59 6.73
w
Tumour size
0.1–1cm 148 13.99 95.54 87.59 2.74 7.95
w
1.1–2cm 470 44.42 89.80 85.26 1.68 4.54
w
2.1 5cm 440 41.59 75.75 72.22 2.20 3.53
ER status
Negative 259 24.48 77.36 74.60 2.75 2.76
Positive 491 46.41 88.53 81.91 1.80 6.62
w
Unknown 308 29.11 84.98 82.24 2.22 2.74
Local therapy
BCS+RT 815 77.03 86.01 82.66 1.35 3.35*
Mast+RT 119 11.25 75.88 65.91 4.46 9.97*
Mast, no RT 124 11.72 85.10 77.89 3.92 7.21
Systemic therapy
None 252 23.82 85.37 80.02 2.58 5.35*
Hormones only 583 55.10 86.42 82.77 1.61 3.65*
Chemotherapy only 83 7.84 77.48 68.90 5.17 8.58
Hormones+chemotherapy 140 13.23 81.08 76.82 3.6 4.26
Abbreviations: BCS¼breast conserving surgery, ER¼oestrogen receptor; RT¼radiotherapy, Mast¼mastectomy. *Po0.05,
wPo0.01.
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sprobability of experiencing a recurrent event was estimated by
applying inflationary factors to the ‘without treatment’ breast
cancer mortality probabilities.
We investigated the representativeness of these US-specific data
and adjustments for breast cancer patients in the United Kingdom,
with a view to ascertaining whether any differences in these
parameters exist between the two countries, and if so whether they
could potentially explain the overestimation of outcomes seen
here. To mirror the way in which Adjuvant! is estimated, the
processes involved in estimating breast cancer mortality (bars 1
and 2 in Figure 2) were considered first, followed by breast cancer
recurrence (bar 3 in Figure 2). Finally, we considered the US–UK
comparability of a number of other factors including life table data
(used by Adjuvant! to estimate other cause mortality), tumour
staging protocol, and treatment effectiveness.
Breast cancer mortality
Adjuvant!’s estimates of breast cancer mortality are central to its
predictions of both OS and BCSS. The overestimation of BCSS
(Table 2) which, recall, is calculated as 100% minus the chance of
dying from breast cancer within 10 years of diagnosis, would seem
to imply that Adjuvant! is underestimating breast cancer mortality
for women in the United Kingdom. The first half of Table 4 further
strengthens this hypothesis by presenting predicted and observed
BCSS for women in the Churchill Hospital data set who did not
Table 3 Comparison of Adjuvant! 10-year event-free survival predictions with observed 10-year outcomes for 1058 women presenting at the Churchill
Hospital in Oxford between 1986 and 1996
Patients % Event-free survival
Demographic, pathologic,
and treatment characteristics No. %
Adjuvant!
prediction Observed s.e. Difference
All patients 1058 100 72.44 68.93 1.46 3.51*
Age, years
20–35 34 3.21 67.37 67.40 8.08  0.03
36–50 362 34.22 72.88 67.86 2.47 5.02*
51–65 452 42.72 72.91 69.60 2.21 3.31
66–75 194 18.34 71.39 68.53 3.60 2.86
X76 16 1.51 72.97 92.31 7.39  19.34*
Menopausal status
Pre 396 37.43 72.40 67.81 2.36 4.59
Post 662 62.57 72.47 69.53 1.86 2.94
Histology
Ductal 794 75.05 72.28 69.16 1.68 3.12
Lobular 115 10.87 72.54 64.19 4.49 8.35
Other 149 14.08 73.26 71.60 3.76 1.66
Grade
1 151 14.27 84.16 86.04 2.90  1.88
2 421 39.79 73.77 68.89 2.31 4.88*
3 244 23.06 64.08 57.60 3.28 6.48*
Unknown 242 22.87 71.26 69.63 2.99 1.63
Nodal involvement
Negative 727 68.71 75.84 73.64 1.67 2.20
Positive 331 31.29 64.98 58.57 2.78 6.41*
Tumour size
0.1–1cm 148 13.99 83.94 80.09 3.31 3.85
1.1–2cm 469 44.33 77.85 74.10 2.08 3.75
2.1–5cm 441 41.68 62.83 59.47 2.40 3.36
ER status
Negative 260 24.57 67.09 61.79 3.06 5.30
Positive 491 46.41 76.57 72.70 2.08 3.87
Unknown 307 29.02 70.38 68.97 2.7 1.41
Local therapy
BCS+RT 816 77.13 73.91 71.50 1.61 2.41
Mast+RT 119 11.25 63.29 57.32 4.65 5.97
Mast, no RT 123 11.63 71.60 62.71 4.61 8.89
Systemic therapy
None 252 23.82 69.64 67.32 3.03 2.32
Hormones only 582 55.01 74.25 72.54 1.91 1.71
Chemotherapy only 83 7.84 67.53 59.12 5.48 8.41
Hormones+chemotherapy 141 13.33 72.91 62.70 4.10 10.21*
Abbreviations: BCS¼breast conserving surgery, ER¼oestrogen receptor; Mast¼mastectomy, RT¼radiotherapy. None of the differences observed for EFS achieved
significance in the Po0.01 level, *Po0.05.
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sreceive any adjuvant systemic therapy. Focussing only upon these
women provides the opportunity to see how well Adjuvant!’s
‘without treatment’ predictions map to the observed outcomes. As
the data show, the programme’s estimates of BCSS are predomi-
nantly greater than observed BCSS and so by convention its
predictions of breast cancer death must be lower.
The two components of Adjuvant!’s ‘without treatment’ breast
cancer mortality predictions are the SEER breast cancer mortality
data and the inflationary adjustment factors used to remove the
effects of unobservable adjuvant therapy (bars 1 and 2 in Figure 2).
Considering the inflation factors first, Table 5 gives the values used
to adjust the observed breast cancer mortality rates of women in
the SEER registry. Inflation factors were estimated for different
nodal status/tumour size combinations by multiplying the prob-
ability that patients with each particular combination would have
received adjuvant therapy by estimates of treatment relative risk
reduction taken predominantly from the 2005 EBCTCG Overview
(Early Breast Cancer Trialists’ Collaborative Group, 2005). The
SEER breast cancer mortality rates of women with node-negative
tumours 1cm in diameter for example were inflated by 8%,
whereas those of women with three positive nodes and a 5cm
tumour were inflated by 33%. As one would expect, the inflation
factors estimated increase as prognosis worsens to reflect the
higher expected usage of adjuvant therapy in these women.
If these inflation factors do not accurately reflect the rates of
adjuvant therapy administration in the United States between 1988
and 1992, more specifically if they were to underestimate the use of
hormone therapy and chemotherapy at that time, then the amount
by which the SEER breast cancer mortality rates are inflated would
be too small and the resulting ‘without treatment’ breast cancer
mortality rates too low, which could potentially explain the
overestimation of outcomes observed by this study. Previously
published studies on the performance of Adjuvant!, however,
indicate that this is not the case (Olivotto et al, 2005; Euler et al,
2006; Schmidt et al, 2009). In the Canadian validation study, for
example, Adjuvant!’s predictions of BCSS for subgroups of patients
who did not receive adjuvant therapy were almost all within 2% of
observed BCSS. This suggests that the programme’s estimates of
‘without treatment’ breast cancer mortality are valid, at least for
patients in British Columbia (Olivotto et al, 2005). Similarly, a
study from Germany that included only axillary node-negative
breast cancer patients (few of whom received adjuvant CMF),
found no significant differences between Adjuvant! predicted and
observed OS across patients with complete 10-year follow-up
(Euler et al, 2006).
These studies would suggest that Adjuvant! can predict breast
cancer mortality accurately both in Canada and Germany. Given
the results reported in this paper, the question is then whether
there are systematic differences in underlying breast cancer
mortality rates between the United Kingdom and the United
States (as well as Canada and Germany) that mean that the SEER
breast cancer mortality rates are not generalisable to patients in
the United Kingdom.
Figure 3 plots age-standardised annual breast cancer mortality
rates for the United Kingdom, the United States, Canada, and
Germany, and shows that from the 1970s onwards, rates in the
United Kingdom have been consistently higher than in the other
three countries (Cancer Information Section – International
Agency for Research on Cancer, 2008). Differences in breast
cancer incidence rates do not appear to explain these trends, with
the rate of new diagnoses in the United Kingdom similar to that
seen in Canada and actually lower than the rate in the United
States (Parkin et al, 2005). Figure 3 shows the differences in
mortality to be particularly pronounced from the 1970s to the start
of the 1990s when death rates from breast cancer increased in the
United Kingdom but remained relatively stable in the United States
and Canada. Although experts have reported that the reasons for
the increases in the United Kingdom are unclear, they have cited
later childbearing, earlier menarche, and other hormonal influ-
ences as potential explanatory factors (Brown, 2000). Whatever the
reasons, breast cancer mortality rates appear lower in the United
States than in the United Kingdom. On this basis, the application
of Adjuvant! Online to breast cancer patients in the United
Kingdom might be expected to result in an underestimation of risk
and consequently an overestimation of prognosis.
Recurrence
In addition to OS and BCSS, Adjuvant! also provided predictions
of EFS for women in the Churchill data set. Event-free survival is
calculated as 100% minus the chance of experiencing a recurrence,
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Figure 1 Ten-year Adjuvant! predicted vs observed outcomes:
(A) shows OS, (B) shows BCSS, and (C) shows EFS.
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sa second primary tumour, or death from breast cancer within 10
years of diagnosis. With recurrence as an event not observable
from the SEER registry, the recurrence rates used in Adjuvant!’s
estimations of EFS are estimated indirectly (bars 2 and 3 in
Figure 2). In the first instance, 14% is added to the mortality risk to
reflect the fact that not all recurrences will result in breast cancer
death. The annual breast cancer mortality rates are then inflated by
a factor of 1.6 for women with ER-positive tumours and 1.1 for
women with ER-negative tumours (Adjuvant! Online, 2005b).
Given the evidence to show that the breast cancer mortality rates
upon which Adjuvant!’s recurrence rates are based could under-
estimate the level of risk facing breast cancer patients in the United
Kingdom, then provided the recurrence inflation factors described
above are generalisable to the United Kingdom (i.e., they
accurately reflect survival prospects following recurrence in the
United Kingdom), one would have expected the magnitude of the
overestimation seen for BCSS to have increased further for EFS.
To demonstrate (albeit oversimplistically), suppose BCSS as
predicted by Adjuvant! and observed in the Churchill Hospital
data set were 85 and 80% respectively. Inflating the associated
breast cancer mortality rates of 15 and 20% by a fixed factor of
say 1.6 (to reflect survival prospects following recurrence) would
generate event rates of 24 and 32%, respectively. The resulting EFS
rates would be approximately 76 and 68% respectively, and the
difference in EFS somewhere in the region of 8% as opposed to the
5% observed for BCSS.
Table 3 however shows that the degree of overprediction for EFS
is on average smaller than for BCSS. For the magnitude of
Adjuvant!’s overprediction to fall when switching from BCSS as an
outcome to EFS, the recurrence rates of women in the Churchill
Hospital data set must be closer to their breast cancer mortality
rates than is postulated by Adjuvant!’s inflation factors. In effect,
the survival prospects of women diagnosed with recurrence at the
Churchill Hospital appear poorer than those of their counterparts
in the United States. One can speculate as to why this might be the
case. It is well known, for example, that clinicians in the United
States are more likely to have access to newer and more effective
therapies before their counterparts in the United Kingdom. The
taxane paclitaxel, for example, was approved by the US Food and
Drug Administration (FDA) as a second-line therapy after the
failure of anthracyclines for distant recurrence, or for patients
relapsing within 6 months of initial breast cancer treatment in 1994
(US Food and Drugs Administration, 2007). In the United
Kingdom, however, not until June 2000 was this drug approved
by the National Institute for Health and Clinical Excellence for the
same indications (National Institute for Health and Clinical
Excellence, 2000). Other agents approved for the treatment of
recurrent breast cancer in the United States before the United
Kingdom, include capecitabine, herceptin, and gemcitabine.
Bevacizumab and lapatinib provide examples of drugs currently
being used in the United States to treat metastatic breast cancer
but not yet approved for use in the United Kingdom. With the
approval and licensing of new and more effective breast cancer
drugs in the United Kingdom lagging years behind the United
States, one might expect there to be differential post-recurrence
survival rates between the two countries. In addition, other factors
that could influence post-recurrence prognosis and which might
conceivably vary between the United States and the United
Kingdom include the frequency and intensity of patient follow-
up, and patient awareness of the symptoms of recurrence.
Other factors
In this section, we consider the US–UK comparability of life table
data, staging protocol, and treatment effectiveness.
When calculating OS, in addition to the breast cancer mortality
rates discussed above, Adjuvant! also makes use of age- and sex-
adjusted US life table data to predict other cause mortality. Moving
from Table 2, which presents BCSS (calculated as 100% minus the
chances of dying from breast cancer within 10 years of diagnosis)
to Table 1, which shows OS (given by 100% minus the chances of
dying from breast cancer or any other cause within 10 years of
diagnosis), one can see that the magnitude of Adjuvant!’s
overestimation tends to increase, albeit only slightly, for example,
across all patients the difference in BCSS of 4.53% increases to just
5.54% for OS. This still suggests however that there may also be
issues surrounding the application of US life table data to UK
patients.
A comparison of life table data from the two countries shows
that for women below the age of 70 years (92% of women in the
Churchill data set), annual mortality risks are virtually identical
(National Centre for Health Statistics, 1998; Government Actuary’s
Department, 2000). For women over the age of 70 years, however,
the risk of dying from any cause is lower for women in the United
States than in the United Kingdom. An 80-year-old woman in the
United States, for example, has a 5% probability of dying before
reaching age 81 years. In the United Kingdom, the corresponding
figure is 5.6%. Although seemingly small, this difference of 0.6%
Other cause 
mortality
Other cause 
mortality
Other cause 
mortality
Breast cancer 
mortality
Breast cancer 
mortality
Recurrence
Alive Alive
Alive and 
recurrence 
free
Outcome data available from
SEER registry
Prediction of 'without treatment' 
breast cancer mortality
Prediction of 'without treatment' 
recurrence
Adjustment 
Adjustment 
Figure 2 Data and processes used to develop the Adjuvant! Online programme.
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swill culminate in a difference of 6% over 10 years. The effect in the
Churchill Hospital data set, however, is far more subtle for a
number of reasons. First, only 8% of patients are over the age of 70
years and will therefore be susceptible to this underestimation.
Second, women in Oxfordshire have lower all-cause mortality rates
than the general UK population (see earlier discussion) and so the
survival of older women in the cohort will be closer to that of their
US counterparts. Nevertheless, when using Adjuvant! to model the
prognosis of older patients, UK users should be aware that the
programme will underestimate other cause mortality, and conse-
quently overestimate OS.
With the staging protocol at the Churchill Hospital requiring the
resection of at least four axillary lymph nodes, and women in the
SEER registry generally having six nodes sampled, the possibility
exists that the women in this study may have been understaged,
that is, classified as node negative when in fact an examination of a
larger number of nodes might have revealed the presence of
cancerous deposits. Further investigation of the Churchill data
Table 4 Comparison of Adjuvant! 10-year predictions and observed breast cancer-specific survival for women presenting at the Churchill Hospital in
Oxford between 1986 and 1996 and who did and did not receive adjuvant systemic therapy
Patients
% Breast cancer-specific survival
without adjuvant systemic therapy Patients
% breast cancer-specific survival
with some adjuvant systemic therapy
Demographic,
pathologic,
and treatment
characteristics No. %
Adjuvant!
prediction observed s.e. Difference No. %
Adjuvant!
prediction Observed s.e. Difference
All patients 252 100 85.37 80.02 2.58 5.35* 806 100 84.57 80.31 1.43 4.26
w
Age, years
p50 112 44.44 83.96 80.95 3.74 3.01 283 35.11 84.36 79.59 2.41 4.77*
51–65 91 36.11 86.74 79.89 4.24 6.85 363 45.04 85.02 82.35 2.04 2.67
X66 49 19.44 86.05 76.82 6.90 9.23 160 19.85 83.93 75.93 3.70 8.0*
Menopausal status
Pre 112 44.44 83.96 80.95 3.74 3.01 283 35.11 84.36 79.59 2.41 4.77*
Post 140 55.56 86.50 79.20 3.58 7.30* 523 64.89 84.69 80.61 1.79 4.08*
Grade
1–2 112 44.44 89.60 82.42 3.67 7.18 460 57.07 88.26 84.21 1.75 4.05*
3 53 21.03 76.00 71.33 6.49 4.67 190 23.57 76.01 69.59 3.44 6.42
Unknown 87 34.52 85.63 82.04 4.21 3.59 156 19.35 84.11 81.78 3.12 2.33
Nodal involvement
Negative 241 95.63 86.24 80.52 2.61 5.72* 488 60.55 89.51 87.09 1.56 2.42
Positive 11 4.37 66.28 68.59 15.15  2.31 318 39.45 77.00 69.95 2.63 7.05
w
Tumour size
0.1–2cm 158 62.70 91.85 82.88 3.06 8.97
w 460 57.07 90.95 86.84 1.61 4.11*
2.1–5cm 94 37.30 74.48 75.10 4.62  0.62 346 42.93 76.10 71.45 2.50 4.65
ER status
Negative 59 23.41 80.22 75.09 5.77 5.13 200 24.81 76.52 74.51 3.12 2.01
Positive 67 26.59 90.03 75.98 5.44 14.05* 424 52.61 88.30 82.84 1.90 5.46
w
Unknown 126 50.00 85.30 84.44 3.29 0.90 182 22.58 84.75 80.80 2.96 3.95
Abbreviation: ER¼oestrogen receptor. *Po0.05,
wPo0.01.
Table 5 Estimates of average treatment relative risk used by Adjuvant! to
adjust for unobserved adjuvant therapy
Group (nodal status/tumour size)
Average relative risk
reduction used by Adjuvant! (%)
(1) (Negative/p1cm) 8
(2) (Negative/1.1–2cm) 16
(3) (Negative/2.1–5cm) 33
(4) (1–3 Positive/p2cm) 33
(5) (1–3 Positive/2.1–5cm) 33
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Figure 3 Age-standardised breast cancer mortality in the United States,
Canada, Germany, and the United Kingdom for women aged 30–74 years.
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showever suggests that this is unlikely to be the case, with no
difference in 10-year BCSS seen between patients classified as node
negative on the basis of less than four nodes sampled (n¼112,
BCSS¼83%, 95% CI 75–89%), four to seven nodes sampled
(n¼309, BCSS¼86%, 95% CI 82–90%), and with more than seven
nodes sampled (n¼308, BCSS¼84%, 95% CI 79–88%). In
addition, although the effect of understaging would manifest for
women classified as node negative (the breast cancer mortality
within this group would be larger than expected and Adjuvant!’s
prognosis predictions for true node-negative patients would then
appear overly optimistic), it could by no means explain the
discordance between predicted and observed OS and BCSS that is
maintained across virtually all demographic, pathologic, and
treatment subgroups.
Finally we consider the published estimates of treatment effect
used in the Adjuvant! programme to model the likely impact of
potential adjuvant therapies. Table 4 shows a comparison of
predicted and observed BCSS for women in the Churchill Hospital
data set who received some form of adjuvant therapy. Here, and in
comparison with women who did not receive adjuvant therapy,
Adjuvant!’s predictions are significantly greater than observed
outcomes for a much larger number of subgroups. Furthermore, it
is interesting to note that for certain subgroups with factors
indicative of a poorer prognosis (i.e., younger age, grade 3, positive
nodal involvement, and tumour size 2.1–5cm), the difference
between predicted and observed BCSS appears much greater once
adjuvant therapies received are entered into the Adjuvant!
programme.
A possible explanation for this is that the estimates of treatment
effect used by the Adjuvant! programme are taken from a meta
analysis of randomised controlled trials (Early Breast Cancer
Trialists’ Collaborative Group, 2005). Although high in internal
validity, the magnitude of the treatment effects reported by such
trials are unlikely to be fully replicable within routine practice
where lower adherence is likely. Many women (440%) routinely
taking tamoxifen, for example, are known to take ‘drug holidays’
on account of the menopausal symptoms they experience as a
result of the drug (Fallowfield, 2005). In contrast although, and
despite a more severe toxicity profile, adherence with chemother-
apy is likely to be higher, as women must usually present at
hospital to receive such treatment intravenously. Although it seems
intuitive that lower adherence to ‘self-administered’ adjuvant
therapies in routine practice would further augment Adjuvant!’s
overpredictions for women in the Churchill Hospital data set
receiving such treatment, one must however bear in mind the
successful validation of Adjuvant! in Canadian patients receiving the
same adjuvant therapies and exposed to the same risk of adverse
events (Olivotto et al, 2005). The question is then whether there are
additional factors in the United Kingdom that mean early breast
cancer patients in this country derive less benefit from treatment
than their counterparts in Canada and the United States?
Limitations
This study is not without its limitations. Although when compared
with some studies evaluating the performance of Adjuvant!, our
study cohort is of a reasonable size, relative to the Canadian
validation study, which included over 4000 patients, our sample
m i g h tb ec o n s i d e r e ds m a l l .T h ei s s u eo fs a m p l es i z ei sp a r t i c u l a r l y
pertinent for the subgroup analyses shown in Tables 1–4. Although
most analyses performed were based upon reasonable numbers of
patients, for a few subgroups, most noticeably women aged 20–35
years and 76 years and over, numbers were low, at 34 and 16
patients, respectively. Similarly, categorising the cohort according to
prognosis predictions (as seen in Figure 1) also resulted in groups
containing small numbers of patients. In both of these cases, the
findings presented should be interpreted with caution.
Also related to the subgroup analyses is the issue of multiple
hypothesis testing. It is widely accepted that the likelihood of
finding a significant difference when one does not truly exist (a
Type I error) increases with the number of significance tests
performed (Altman, 1999). In this study, where over 30 such tests
were performed separately for OS, BCSS, and EFS, one must
consider the possibility that some of the differences between
predicted and observed outcomes that were significant at the 5%
level are in fact spurious. From the published literature it is not
clear how best to deal with the issues posed by multiple
significance testing. Bonferroni adjustments have been advocated
as one means of reducing type I errors; however, this has been
shown to be at the expense of increasing type II errors (accepting
that there is no difference when in fact the opposite is true). The
technique has also been criticised for testing irrelevant hypotheses
and leading to inferences which defy common sense (Perenger,
1998). Acknowledging the potential impact of multiple testing in
this study, we evaluated our results using a stricter criterion for
statistical significance of Po0.01, in addition to the conventional
level of Po0.05. Tables 1 and 2 (OS and BCSS) show that many of
the differences significant at the 5% level, remained significant at
the 1% level. For EFS, however (Table 3), none of the differences
observed were significant at the 1% level.
CONCLUSION
Adjuvant! Online is a valuable application capable of generating
10-year prognosis predictions in the absence and presence of
adjuvant systemic therapy. The programme was developed in the
United States and has been shown to perform well in Canada and
Germany. This study however has demonstrated that when applied
to a cohort of women treated at Oxford’s Churchill Hospital in the
United Kingdom, Adjuvant! generated prognosis predictions,
which were overoptimistic. A systematic difference in the under-
lying breast cancer mortality rates between the United States and
the United Kingdom would appear to provide the main explana-
tion for why a straightforward application of the programme to a
cohort of patients in the United Kingdom appears not to perform
as well as expected. Data to suggest that these differences in breast
cancer mortality can be partly explained by poorer post-recurrence
survival rates in the United Kingdom, also illustrate the wider and
more rapid availability of new therapies in the United States than
in the United Kingdom.
With clinicians in the United Kingdom increasingly making
use of Adjuvant! as an aid to clinical decision making, further
research is required to ascertain whether the findings reported
here are indeed generalisable to other areas of the United
Kingdom. If found to be the case, then one must consider whether
certain women may be being advised against adjuvant chemother-
apy on the basis of overoptimistic prognosis predictions.
Adjustments to the input parameters within the Adjuvant! model
so as to produce a UK-specific version could offer one potential
solution to this.
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